ADIAL PHARMACEUTICALS, INC. (ADIL) SEC Filings

Adial Pharmaceuticals, Inc. (ADIL) reported granting a stock option as a material inducement for a new employee to join the company. On August 19, 2026, the company granted an option to purchase 307,814 shares of common stock at an exercise price of $5.76 per share, the closing price on the grant date. The option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to continued service. The grant was made outside the company’s equity incentive plans under the employment inducement exception in Nasdaq Listing Rule 5635(c)(4) and relies on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D. The option and underlying shares may not be sold in the United States without registration or an applicable exemption.

ADIAL PHARMACEUTICALS, INC. (symbol: ADIL) is the issuer of record for a Form DEF 14A filing submitted to the SEC.

ADIAL PHARMACEUTICALS, INC. (ADIL) disclosed that on August 18, 2026 it received a Nasdaq notice that its stockholders’ equity, as reported in its June 30, 2026 Form 10-Q, no longer meets the $2,500,000 minimum required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The notice also states the company does not meet the alternative standards of a $35 million market value of listed securities or $500,000 in net income from continued operations in the required periods. The company has 45 days, until October 2, 2026, to submit a compliance plan and may receive up to a 180-day extension if Nasdaq accepts the plan. Adial anticipates seeking stockholder approval at its 2026 Annual Meeting to convert outstanding Series A Non-Voting Convertible Preferred Stock as a potential means to restore stockholders’ equity but cautions that there is no assurance it will regain or maintain compliance or avoid delisting.

Adial Pharmaceuticals, Inc. reported its business update for the quarter ended June 30, 2026, alongside second-quarter 2026 results. The company completed the acquisition of Azora Therapeutics, adding lead program AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor agonist being developed for ulcerative colitis.

Adial also closed the first $32 million tranche, including conversion of $5.5 million of notes, of an up to $64 million private financing from biotechnology-focused institutional investors, which it states will support advancement of AT177 through key development milestones. Following the Azora acquisition, Adial’s strategy shifts toward serious inflammatory diseases, with AT177 in IND-enabling studies and an investigational new drug filing planned for the first half of 2027, a Phase 1a SAD/MAD trial planned for the second half of 2027, and a subsequent Phase 1b proof-of-concept study in ulcerative colitis patients. The company indicates that existing cash and cash equivalents are expected to fund operating expenses into the second half of 2027.

Adial Pharmaceuticals, Inc. reported a sharp expansion of its balance sheet in the six months ended June 30, 2026 driven by the acquisition of Azora Therapeutics and a concurrent private placement, while recording a large non‑cash R&D charge and maintaining substantial going‑concern risk.

Total assets rose to $29.1 million from $6.7 million, with cash and equivalents increasing to $28.7 million, funded mainly by $26.8 million of pre‑funded warrant financing. The Azora transaction added a lead inflammatory bowel disease candidate, AT177, but resulted in $46.2 million of acquired in‑process R&D expense, contributing to a six‑month net loss of $54.0 million and a stockholders’ deficit of $38.4 million.

The company now carries a $23.8 million milestone warrant rights liability and $38.5 million of Series A preferred stock classified as temporary equity, which may require cash settlement if shareholder approval for conversion and timely share delivery is not obtained. Management explicitly concludes there is substantial doubt about Adial’s ability to continue as a going concern over the next 12 months without additional financing.

Adial Pharmaceuticals, Inc. outlines anticipated leadership and governance changes tied to its 2026 annual meeting of stockholders. As of August 10, 2026, the company anticipates that, if specified proposals receive stockholder approval at the 2026 Annual Meeting, the employment of current President and Chief Executive Officer Cary Claiborne and current Chief Financial Officer Vinay Shah will be terminated promptly after the meeting. The company expects to appoint Matthew Davidson, currently Chief Development Officer and a director, as the new President and Chief Executive Officer, and to appoint a new Chief Financial Officer. Upon termination and subject to execution of a release, Messrs. Claiborne and Shah would receive severance payments and benefits under their amended and restated employment agreements.

The company also anticipates changes to the size and composition of the Board of Directors following stockholder approval, including resignations of legacy board members and replacement with new directors, although no definitive determinations have been made. The 2026 annual meeting is scheduled for September 17, 2026, and stockholder proposals or director nominations, whether under Rule 14a-8 or otherwise, must be received by August 23, 2026 to be considered timely.

Adial Pharmaceuticals completed the acquisition of Azora Therapeutics on June 11, 2026 in a stock‑for‑stock Merger and is now seeking stockholder approvals tied to that transaction and related financings. Azora holders received 437,421 shares of common stock and 12,930.617 shares of Series A Non‑Voting Convertible Preferred Stock, each convertible into 1,000 common shares, plus 1,177,782 assumed options subject to approval. Concurrently, Adial raised approximately $26.8 million via Initial Closing pre‑funded warrants and arranged additional Milestone pre‑funded and incentive warrants, as well as an exchange of $5.5 million of Azora notes into pre‑funded warrants.

At the 2026 Annual Meeting, investors are asked to elect two directors, ratify the auditor, approve multiple share‑issuance proposals for the Series A conversion, assumed options, PIPE and Azora note warrants, Series F warrants, increase authorized common shares from 100 million to 500 million, adopt or expand equity and employee stock purchase plans, and allow adjournment if needed. If all proposals are approved, up to 53,415,811 additional shares could be issued or reserved. On a fully diluted, as‑converted basis, legacy Adial equityholders are expected to own about 7.7% of the combined company, former Azora holders 51.0%, and financing investors (including Azora noteholders) 41.3%.

Post‑Merger, Adial’s primary focus is Azora’s lead asset AT177, a colon‑targeted aryl hydrocarbon receptor agonist for ulcerative colitis, with an IND planned for the second quarter of 2027 and early proof‑of‑concept data targeted for the first half of 2028. The company also effected a 1‑for‑25 reverse stock split on February 5, 2026 and may change its name to Azora Therapeutics, Inc. and its Nasdaq ticker to “AZR” if the Transaction Stockholder Matters and Nasdaq listing application are approved.

Adial Pharmaceuticals, Inc. filed an amended report to add the historical financial statements of its newly acquired subsidiary Azora Therapeutics, Inc. and unaudited pro forma condensed combined financial information following completion of their June 11, 2026 merger. The amendment includes Azora’s audited financials for 2025 and 2024, unaudited results for the quarter ended March 31, 2026, and combined pro forma statements for 2025 and the first quarter of 2026. Azora is a pre‑revenue biopharmaceutical company focused on autoimmune diseases, with a 2025 net loss of $0.7 million and year‑end cash of $0.3 million, and its auditors highlight substantial doubt about its ability to continue as a going concern. The notes describe the merger consideration and a concurrent PIPE financing under which Adial issued pre‑funded and incentive warrants for gross proceeds of about $26.8 million, with the potential for an additional $26.8 million and the extinguishment of $5.5 million of Azora convertible notes through warrant exchanges.